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Objectives: The aim of the study was to describe the effects of aripiprazole, a new atypical 
antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive 
functions in patients with genetically conﬁ  rmed Huntington’s disease (HD).
Methods and results: Three HD patients were evaluated for Uniﬁ  ed Huntington Disease 
Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and 
one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric 
symptoms, with effects on cognitive functions.
Conclusions: Our case reports suggest that aripiprazole is well tolerated, remarkably improving 
some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, 
long-term studies are warranted.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder 
caused by the expansion of a CAG trinucleotide repeat in the IT-15 gene on the 
short arm of chromosome 4. The classic HD presentation includes midlife onset 
of dementia, personality disorders, and chorea. Dystonia and parkinsonism usually 
become evident later, during the course of the disease. The mainstay therapy for 
controlling the choreic disorder in HD is based on antidopaminergic agents.1,2 
Nevertheless classic antipsychotics may induce extrapyramidal symptoms and 
cognitive slowing down that increase functional disability.3 Several studies suggest 
that atypical neuroleptics, mainly risperidone and olanzapine, having a lower rate 
of neurological side-effects than typical neuroleptics, could be useful in improving 
chorea and psychiatric symptoms in HD patients.4–10 However, recent reports have 
raised concerns about a possible association between atypical antipsychotic drugs 
and adverse metabolic changes.11
Aripiprazole, a new second-generation antipsychotic agent, acts as a partial agonist 
on dopaminergic D2 and serotoninergic 5HT1A receptors and as antagonist on the 
5HT2A receptors.12,13 The use of aripiprazole for the treatment of neurological and/or 
psychiatric conditions is disclosed in WO/2008/038003 that includes statements 
indicating the potential usefulness of this drug in Huntington’s disease. Owing 
to its peculiar neuropharmacological proﬁ  le, aripiprazole is well tolerated, rarely 
inducing extrapyramidal and metabolic adverse effects when used in schizophrenic 
patients.14,15
In this paper, we report a series of three patients with genetically conﬁ  rmed HD 
in whom aripiprazole effectively controlled involuntary movements and psychiatric 
symptoms with effects on cognitive functions.Neuropsychiatric Disease and Treatment 2009:5 2
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Clinical assessment
To quantify the effectiveness of aripiprazole in controlling 
the movement disorder, the following categories of the 
Unified Huntington’s Disease Rating Scale (UHDRS) 
part I were separately analyzed: oculomotor function (ocular 
pursuit, saccade initiation, saccade velocity); hyperkinesias 
(chorea, dystonia, tongue protrusion, and dysarthria); ﬁ  ne 
motor tasks (ﬁ  nger taps, pronate/supinate hands, Luria test); 
parkinsonism (rigidity and bradykinesia); and gait (gait, 
tandem walking, retropulsion test).16 Cognitive function was 
assessed with the UHDRS part II.16 Behavioral changes were 
assessed with the Beck Depression Inventory (BDI).17 The 
baseline and the follow-up visits (after two months and one 
year treatment) were made by the same neurologist (A.C.). 
Clinical assessments are reported in Table 1. The patients 
and their families gave permission to use these data for 
research.
Case 1
A 56-year-old man carrying a 47 CAG repeat mutation, began 
in 2001 to experience a progressive choreic disorder and depres-
sion, so antidepressant treatment with sertraline (50 mg/day) 
was started. Five years later, when his movement disorder led 
to social embarrassment and difﬁ  culties at work, he started 
neuroleptic treatment ﬁ  rst with risperidone (2 mg/day) switched 
six months later to olanzapine (5 mg/day). Unfortunately, both 
treatments caused adverse side effects (apathy and depres-
sion on risperidone and a severe metabolic syndrome with 
hepatosteatosis on olanzapine treatment), therefore both drugs 
were stopped. After a one-month washout period, neurological 
assessment was conducted and aripiprazole was then started 
at a dose of 2.5 mg/day, and increased to 7.5 mg/day over 
two months. Selective serotonin reuptake inhibitors (SSRI) 
treatment remained unchanged during the whole time of 
evaluation. Two months later the patient had achieved good 
control of hyperkinesias, with no evidence of side effects or 
extrapyramidal adverse events. The caregiver reported that the 
patient’s interest in home and work activities had improved.
After the one-year treatment, neurological examination 
conﬁ  rmed the beneﬁ  t of aripiprazole, and the patient reported 
no adverse effects. Cognitive function also slightly improved 
(UHDRS part II total score at baseline = 89.2 and after 
1 year = 98.2) and the patient’s BDI scores showed a signiﬁ  -
cant improvement in depression (12 at baseline and 5 after 
1 year). The hematological follow-up assessment showed 
that the metabolic syndrome had almost been resolved, and 
hepatosteatosis markedly improved.
This case report has had some of its data previously 
published as part of a conference proceedings.18
Case 2
A 68-year-old woman with a genetically conﬁ  rmed diagnosis 
of HD (46 CAG repeats) was referred to our Department in 
December 2006. She had a 10–15-year history of progressive 
choreiform movements and behavioral changes. She progres-
sively became dependent on caregivers for performance of 
all activities of daily living (ADLs). Olanzapine (5 mg/day) 
and lorazepam (1.5 mg/day at bedtime) were started in 2005 
to treat chorea and behavioral symptoms, initially resulting in 
good control of behavioral (agitation, anxiety, and insomnia) 
and motor symptoms. Within one year the beneﬁ  t waned 
Table 1 Clinical parameters of Huntington’s disease patients treated with aripiprazole
Patient Daily dose Total motor score Oculomotor function Hyperkinesias
Baseline Two months One year Baseline Two months One year Baseline Two months One year
Case 1 7.5 mg 50 26 (−48%) 28 (−44%) 9 4 (−56%) 4 (−56%) 25 11 (−56%) 10 (−60%)
Case 2 15 mg 112 96 (−14%) 98 (−13%) 24 24 24 51 35 (−31%) 37 (−27%)
Case 3 7.5 mg 97 61 (−37%) 64 (−34%) 23 16 (−30%) 17 (−26%) 43 21 (−51%) 23 (−46%)
Fine motor tasks Parkinsonism Gait
Baseline Two months One year Baseline Two months One year Baseline Two months One year
9 5 (−44%) 7 (−22%) 33 3 43 (−25%) 4
20 20 20 5 5 5 12 12 12
19 14 (−26%) 14 (−26%) 44 4 86 (−25%) 6 (−25%)
To quantify the effectiveness and possible adverse effects of aripiprazole treatment, total motor score and the following categories of the Uniﬁ  ed Huntington’s Disease Rating 
Scale (UHDRS) part I were separately analyzed: oculomotor function (ocular pursuit, saccade initiation, saccade velocity), hyperkinesias (chorea, dystonia, tongue protrusion 
and dysarthria), ﬁ  ne motor tasks (ﬁ  nger taps, pronate/supinate hands, Luria test), parkinsonism (rigidity and bradykinesia), and gait (gait, tandem walking, retropulsion test). 
UHDRS scores at baseline (left column), after two months (central column) and one year (right column) aripiprazole treatment are reported.Neuropsychiatric Disease and Treatment 2009:5 3
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and increasing the olanzapine dose (up to 15 mg) failed to 
induce further beneﬁ  ts.
On admission to our department, the patient was in a 
wheelchair and her speech was mostly incomprehensible. 
She had severe upper limb choreathetosis, involuntary 
facial muscle and tongue movements with severe dysphagia. 
Olanzapine was tapered and neurological assessment was 
performed after a washout period of 15 days. Aripiprazole 
was then started at a dose of 5 mg/day and increased 
to 15 mg/day over two months. By the second month of 
treatment, UHDRS subtotal hyperkinesias score decreased 
from 51 to 35. Notably, as choreic tongue movements 
decreased, dysphagia also improved. The caregivers reported 
an improvement in the quality of both sleep and diurnal 
agitation. Clinical follow-up after the one-year treatment 
conﬁ  rmed good control of motor symptoms without adverse 
effects. Cognitive and psychiatric assessment in this patient 
was not possible due to severe cognitive dysfunctions encom-
passing severe impairment of attention, oral comprehension 
and executive functions.
Case 3
The patient, a 68-year-old woman diagnosed 10 years 
previously with HD (45 CAG repeats), was referred to 
our department in 2001. She had severe chorea, dystonic 
posture, gait difﬁ  culties, and moderate dysarthria. She was 
partially dependent on the caregiver for ADLs. On admis-
sion to our department and during the period of the study 
she was taking paroxetine 20 mg/day. To treat the move-
ment disorder aripiprazole was started in December 2006 
and gradually titrated up to 7.5 mg daily. After the patient 
received 5 mg/day, her choreic movements began to improve. 
After two months of aripiprazole 7.5 mg/day, the UHDRS 
hyperkinesias score markedly improved (from 43 to 21). 
The patient remained stable during the 12-month treatment 
and reported no side effects. Furthermore we observed a 
moderate improvement in cognitive assessment (UHDRS 
part II total score at baseline = 49.7 and after 1 year = 69.7) 
and a signiﬁ  cant improvement in depression (BDI score at 
baseline = 24 and after 1 year = 15). Anxiety also came under 
acceptable control.
Discussion
This is to our knowledge the ﬁ  rst report describing the 
beneﬁ  cial symptomatic effects of the novel antipsychotic 
drug aripiprazole on motor, psychiatric, and cognitive 
symptoms in three patients affected by HD. The mecha-
nism through which aripiprazole acted to improve patients’ 
chorea remains elusive. Aripiprazole is a dopamine 
neurotransmitter stabilizer acting as a functional antago-
nist in hyperdopaminergic and, conversely, as a functional 
agonist in hypodopaminergic states.19,20 In our small cohort 
of patients, the drug may have controlled the involuntary 
movements related to HD by antagonizing striatal D2 and 
D3 receptors.21
In agreement with several reports,14,15,22 aripiprazole also 
protected our patients from extrapyramidal side effects, 
probably owing to its pharmacodynamic proﬁ  le – ie, partial 
agonist on dopaminergic D2 and on serotoninergic 5HT1A 
receptors and antagonist on the 5HT2A receptors – reducing 
the antagonist load at the nigrostriatal pathway level.12,13 
Notably, the improvement in apathy, anxiety, and depression 
could depend on aripiprazole’s action in modulating central 
serotoninergic pathways.23–25
Our report also underlines another advantage of 
aripiprazole. In the first patient we treated in this 
series, switching to aripiprazole resolved the possible 
olanzapine-induced metabolic dysfunction. In agreement 
with our ﬁ  ndings, previous reports have suggested that the 
risk of metabolic dysfunction is reduced in patients treated 
with aripiprazole compared to other atypical neuroleptics.11,26 
Efﬁ  cacy on cognitive functions is heralded but further 
clinical evidence is needed.
Despite normal ﬂ  uctuations in motor symptoms occur-
ring in HD along the course of the disease, the beneﬁ  ts we 
obtained in these three patients over the 12 months follow-up 
may be considered an indicator of the efﬁ  cacy of aripiprazole 
in HD. Further evidence clearly awaits conﬁ  rmation from 
a larger study. Notwithstanding this caveat, considering 
aripiprazole’s known dopamine stabilizing properties, the 
beneﬁ  cial symptomatic effects we report on both motor and 
behavioural manifestations suggest investigating whether this 
drug might beneﬁ  t voluntary movements, other than chorea. 
If so, considering that in one of our patients it improved 
apathy, a behavioural disturbance severely affecting patients’ 
independence in mild-to-advanced HD stages, aripiprazole 
might be an interesting novel symptomatic option that could 
be combined with other drugs speciﬁ  cally acting on chorea, 
such as tetrabenazine.27
In conclusion, our case reports suggest that aripiprazole 
is well tolerated, remarkably improving some of the 
motor and behavioral symptoms in patients affected by 
HD. Randomized, controlled, long-term studies are war-
ranted to further investigate the effectiveness of this 
atypical neuroleptic in the symptomatic treatment in patients 
with HD.Neuropsychiatric Disease and Treatment 2009:5 4
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